EMD Serono Research & Development Institute, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$26.7M
Doctors Paid
208
Transactions
3,919
2024 Total
$1.7M
Payment Breakdown by Category
Research$25.0M (93.6%)
Consulting$1.5M (5.7%)
Travel$98,834 (0.4%)
Food & Beverage$17,585 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $25.0M | 3,075 | 93.6% |
| Consulting Fee | $1.5M | 317 | 5.7% |
| Travel and Lodging | $98,834 | 213 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $71,405 | 15 | 0.3% |
| Food and Beverage | $17,585 | 296 | 0.1% |
| Entertainment | $2,809 | 3 | 0.0% |
Payments by Type
Research
$25.0M
3,075 transactions
General
$1.7M
844 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| EMR 100070-001 | $8.4M | 0 | 904 |
| EMR 200647-001 | $3.7M | 0 | 355 |
| MS 200527-0018 | $1.4M | 0 | 157 |
| EMR 100070-007 | $1.2M | 0 | 202 |
| DNA Damage Repair (DDR) Inhibitor-Based Basket of Baskets Trial in Patients with Advanced Solid Tumors Harboring Aberrations in DDR Genes (D-BOB) | $1.2M | 0 | 1 |
| EMR 100070-005 | $1.0M | 0 | 123 |
| EMR 100018-001 | $840,547 | 0 | 173 |
| EMR 100070-003 | $561,890 | 0 | 84 |
| EMR 100070-008 | $479,269 | 0 | 88 |
| EMR 100070-004 | $457,623 | 0 | 58 |
| MS 200095-0022 | $433,246 | 0 | 133 |
| EMR 700461-023 | $400,817 | 0 | 51 |
| A multicenter, randomized, double-blinded, placebo-controlled, Phase 3 trial of adjuvant Avelumab (anti-PDL-1 antibody) in Merkel cell carcinoma patients with clinically detected lymph node metastases | $367,000 | 0 | 1 |
| 19-010887 MC1821 MCR Lead Site Docetaxel plus Bintrafusp alfa or placebo for NSCLC | $364,067 | 0 | 1 |
| Phase I Trial with Expansion Cohort of DNA PK Inhibition and IMRT In Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | $354,239 | 0 | 1 |
| CTLA4-Ig-Anti-OX40L fusion for GVHD Prevention | $325,000 | 0 | 1 |
| An Open-Label phase I/II study to evaluate the safety and preliminary efficacy of amivantamab and tepotinbib combination in MET-altered non-small cell lung cancer (NSCLC) | $318,414 | 0 | 1 |
| Phase II Trial of Xevinapant in Combination with Post-Operative Cisplatin and Radiotherapy for High Risk Head and Neck Cancer | $303,095 | 0 | 1 |
| EMR 200017-014 | $277,229 | 0 | 80 |
| MS 201923-0001 | $217,979 | 0 | 29 |
| EMR 200592-006 | $175,530 | 0 | 1 |
| A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib Compared withTeriflunomide, in Participants with RelapsingMultiple Sclerosis to Evaluate Efficacy and Safety | $161,433 | 4 | 9 |
| IDIO Study, AWD-007285 | $157,201 | 0 | 1 |
| Defining the role of BTK in meningeal inflammation - from meningeal B cells to tertiary follicle like structures | $144,054 | 0 | 2 |
| Phase 2 trial to evaluate combination therapy with pemetrexed and avelumab in previously treated patients with MTAP-deficient metastatic urothelial cancer | $136,326 | 0 | 1 |
| EMR 700461-024 | $131,126 | 0 | 238 |
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus Participants Receiving Standard of Care | $121,175 | 4 | 14 |
| MS 200527-0081 | $109,099 | 0 | 24 |
| PROTRACT | $104,220 | 0 | 21 |
| MS 700461-0035 | $102,135 | 0 | 129 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Joan Merrill, Md, MD | Rheumatology | Oklahoma City, OK | $166,950 | $0 |
| Dr. Stephen Krieger, Md, MD | Neurology | New York, NY | $131,639 | $0 |
| Devalingam Mahalingam, M.d, M.D | Internal Medicine | Chicago, IL | $54,240 | $0 |
| Stephen Pappas, M.d, M.D | Internal Medicine | Houston, TX | $53,500 | $0 |
| Dr. Peter Bergethon, M.d, M.D | Neurology | Boston, MA | $51,000 | $0 |
| Dr. Arkadiusz Dudek, M.d, M.D | Internal Medicine | Rochester, MN | $50,507 | $0 |
| Taofeek Owonikoko, M.d, M.D | Hematology & Oncology | Pittsburgh, PA | $48,501 | $0 |
| Paul Bunn, Md, MD | Medical Oncology | Aurora, CO | $46,084 | $0 |
| Dr. Enrique Alvarez, Md, Phd, MD, PHD | Neurology | Aurora, CO | $43,043 | $0 |
| Naga Chalasani, Md, MD | Internal Medicine | Indianapolis, IN | $42,000 | $0 |
| Barry Gertz, Md, MD | Endocrinology, Diabetes & Metabolism | Rahway, NJ | $41,675 | $0 |
| Everett Vokes | Hematology & Oncology | Chicago, IL | $38,484 | $0 |
| Philip Schein, M.d, M.D | Medical Oncology | Bryn Mawr, PA | $35,244 | $0 |
| Lee Simon, M.d, M.D | Rheumatology | Boston, MA | $33,312 | $0 |
| Dr. George Demetri, Md, MD | Medical Oncology | Boston, MA | $33,311 | $0 |
| James Lewis, Md, MD | Urology | Macon, GA | $29,100 | $0 |
| Richard Goldberg, Md, MD | Medical Oncology | Morgantown, WV | $28,337 | $0 |
| John Heymach, M.d, M.D | Internal Medicine | Houston, TX | $26,650 | $0 |
| Unknown Provider | — | — | $24,900 | $0 |
| Mark Genovese, M.d, M.D | Rheumatology | Stanford, CA | $23,162 | $0 |
| Dr. Joel Tepper, Md, MD | Radiation Oncology | Chapel Hill, NC | $21,986 | $0 |
| Dr. Adam Dicker, M.d, M.D | Radiation Oncology | Philadelphia, PA | $21,078 | $0 |
| Dr. Bruce Chabner, Md, MD | Internal Medicine | Boston, MA | $20,835 | $0 |
| Vibeke Strand, M.d, M.D | Rheumatology | Portola Valley, CA | $19,950 | $0 |
| Samuel Cohen, Md, Phd, MD, PHD | Anatomic Pathology & Clinical Pathology | Omaha, NE | $18,903 | $0 |
Ad
Top Products
- Bavencio $12.4M
- MSB0011359C $3.7M
Associated Products (2)
- MSB0011359C $6.7M
- Evofosfamide $175,530
Payment Categories
- Food & Beverage $17,585
- Consulting $1.5M
- Travel & Lodging $98,834
- Research $25.0M
About EMD Serono Research & Development Institute, Inc.
EMD Serono Research & Development Institute, Inc. has made $26.7M in payments to 208 healthcare providers, recorded across 3,919 transactions in the CMS Open Payments database. In 2024, the company paid $1.7M. The top product by payment volume is Bavencio ($12.4M).
Payments were distributed across 39 medical specialties. The top specialty by payment amount is Internal Medicine ($343,612 to 33 doctors).
Payment categories include: Food & Beverage ($17,585), Consulting ($1.5M), Research ($25.0M), Travel & Lodging ($98,834).
EMD Serono Research & Development Institute, Inc. is associated with 2 products in the CMS Open Payments database.